by Erik Valent | Jan 2, 2020 | Uncategorized
Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients Yan-Ting Chen1, Erik T. Valent1, Erik H. van Beers1, Rowan Kuiper1, Stefania Oliva2, Torsten Haferlach3, Wee-Joo Chng4, Martin H....
by Erik Valent | Jul 31, 2019 | Uncategorized
In two video interviews – recorded by the Myeloma Patients Europe – Dr. Annemieke Van Dongen-Leunis from the Erasmus School of Health Policy and Management, Erasmus University Rotterdam, explains the results of the research conducted within the MMpredict...
by Erik Valent | Jul 31, 2019 | Uncategorized
Watch the interesting webinar on personalised medicine organized by Myeloma Patients Europe (MPE). In this webinar, Dr Annemiek Broijl from the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands – provided examples of the...
by Erik Valent | Jun 18, 2019 | Uncategorized
One day in advance of the 24th EHA congress in Amsterdam, The Netherlands, we have had the opportunity to host our fifth HORIZON 2020 MMpredict consortium meeting. During this interactive session valuable input was exchanged amongst the project partners. We would like...
by Erik Valent | Jun 13, 2019 | Uncategorized
The Horizon 2020 MMpredict initiative was started on November 1st 2016 and included the following consortium partners: SkylineDx B.V., the Department of Haematology of the Erasmus University Medical Centre Rotterdam (Erasmus MC), the Department of Onco-Haematology of...
